Table 2 In-hospital acute treatment, coronary revascularisation and evidence-based pharmacotherapy
Active smokers | Non-smokers | P value | |
|---|---|---|---|
Thrombolysis | |||
Given | 7239 (77.1 %) | 3826 (69.0 %) | <0.001 |
Not given—proceeded to primary angioplasty | 891 (9.5 %) | 627 (11.3 %) | |
Not given—missed | 961 (10.2 %) | 807 (14.6 %) | |
Not given—patient refusal | 34 (0.4 %) | 20 (0.4 %) | |
Not given—contraindicated | 269 (2.9 %) | 252 (4.5 %) | |
Door to needle time (median) | 45 (26–82) | 50 (30–94) | <0.001* |
STEMI | |||
Percutaneous coronary intervention | 2679 (29.8 %) | 1541 (29.2 %) | <0.001 |
NSTEMI | |||
Percutaneous coronary intervention | 566 (21.6 %) | 773 (16.7 %) | <0.001 |
Evidence-based Medications | |||
Aspirin | 10,445 (93.8 %) | 8370 (87.9 %) | <0.001 |
ADP-antagonist | 6629 (78.4 %) | 5462 (73.0 %) | <0.001 |
ACE-I/ARB | 6575 (53.4 %) | 5422 (52.3 %) | 0.080 |
Beta blocker | 7301 (68.4 %) | 6350 (68.2 %) | 0.761 |
Statin | 10,024 (90.5 %) | 8179 (86.3 %) | <0.001 |